Abbott Laboratories Shares Slide Following Q1 Earnings Miss

Apr 16, 2026 13:53 UTC

ABT

Short term

Abbott Laboratories saw its stock price drop over 4% after reporting a decline in first-quarter net income. Despite the earnings dip, the company reported a year-over-year increase in total revenue.

Net income dropped to $1.07 billion from $1.32 billion
Earnings per share fell from $0.76 to $0.61
Revenue grew to $11.16 billion from $10.35 billion
2026 adjusted EPS guidance projected at $5.38-$5.58
Stock price fell 4.21% to $97.21

Shares of Abbott Laboratories (ABT) fell approximately 4.21% on Thursday morning, trading at $97.21 following the release of its first-quarter financial results. The decline reflects investor reaction to a drop in net income compared to the same period last year. The company reported Q1 earnings of $1.07 billion, translating to $0.61 per share. This represents a notable decrease from the $1.32 billion, or $0.76 per share, recorded in the prior year's first quarter. In contrast to the earnings decline, Abbott's top-line growth remained positive. Revenue for the quarter rose to $11.16 billion, up from $10.35 billion a year ago. Looking ahead, the company provided guidance for the full year 2026, projecting adjusted earnings per share (EPS) between $5.38 and $5.58. The stock's current price of $97.21 sits near the bottom of its 52-week trading range of $96.82 to $139.06. The market's reaction underscores a sensitivity to bottom-line performance despite the growth in overall sales.